 |
|
|
| |
Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis - AASLD-EASL Special HCV Conference Miami
|
| |
| |
Reported by Jules Levin
Presented at the AASLD/EASL HCV Special Conference, February 1-2, 2019, Miami, Florida, United States
Francesco Negro1, Michael P Curry2, Heiner Wedemeyer3, Jose A Carrión4, Marcello Persico5, Pietro Lamperti co6, Markus Cornberg7, Ashley Brown8, Nicole Wick9, Andreas Pangerl10, Lois Larsen10, Yao Yu10, Juan Turnes11
1Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Geneva, Switzerland; 2Beth Israel Deaconess Medical Center, Boston, Massachusett s, United States; 3University Clinic Essen, Essen, Germany; 4Liver Secti on, Gastroenterology Department, Hospital del Mar, Hospital del Mar Medical Research Insti tute, Universitat Autonoma de Barcelona, Barcelona, Spain; 5Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy; 6CRC "A. M. and A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; 7Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 8Imperial College Healthcare NHS Trust, London, United Kingdom; 9Trio Health, La Jolla, California, United States; 10AbbVie Inc., North Chicago, Illinois, United States; 11Department of Gastroenterology and Hepatology, C.H.U. Pontevedra and IIS Galicia Sur, Pontevedra, Spain
|
| |
|
|
|
|
|
